Ultima Genomics Unveils Revolutionary Sequencing Technology at ASHG 2026

Ultima Genomics Unveils Groundbreaking Sequencing Technology at ASHG 2026

Ultima Genomics has made waves in the genomics community with their latest announcement during the American Society of Human Genetics (ASHG) 2026 Annual Meeting. The company introduced paired-end sequencing capabilities on the UG200™ Series and launched Solaris™ 2.0 Max sequencing consumables. This technology advancement is significant for researchers and clinical labs as it doubles the output compared to existing workflows and paves the way for the $60 human genome sequencing.

Advancing Workflow Compatibility and Quality

Paired-end sequencing is a method where both ends of each DNA fragment are read, improving the accuracy of read mapping, particularly in complex and repetitive areas of the genome. This capability enhances the quality and compatibility of genome analysis, thus supporting various applications such as germline whole genome sequencing (WGS) and other important analyses. The UG200 Series, combined with Solaris 2.0 Max, allows for the sequencing of up to 60,000 human genomes annually at 30x coverage using a single instrument.

The Solaris 2.0 Max platform has shown remarkable performance by delivering up to 20 billion reads per wafer, effectively doubling the capacity of previous Solaris workflows. This increase in output not only supports large-scale genomic projects but also helps clinical applications that require high-quality data at an affordable price.

Significant Partnerships and Projects

Ultima's technology is already being put to great use, notably in the ambitious Precure initiative, which involves generating an extensive human multi-omic biomedical dataset through a collaboration with the Mayo Clinic and Thermo Fisher Scientific. This initiative aims to produce one million samples to further drive AI and machine learning discoveries in genomics.

In another exciting development, Ultima is working with NVIDIA to create a pangenome-aware analysis workflow that utilizes Google's DeepVariant. This collaboration seeks to benchmark new pangenome alignment methods against traditional approaches, leveraging genetically diverse human genomes to improve accuracy.

Enhanced Capabilities for Clinicians

The feedback from early users of the paired-end sequencing and Solaris 2.0 Max has been overwhelmingly positive. Clinical laboratories are particularly excited about the significant increase in data quality.

David Schlesinger, CEO of Mendelics, pointed out that they have noticed substantial quality improvements in their germline applications. Additionally, Ajamete Kaykas from Insitro indicated that the capability to generate massive amounts of data quickly and affordably is transformative for their current experimental setups.

Community Engagement at ASHG 2026

Ultima will host a User Group Meeting and Workshop during ASHG 2026, designed to engage the user community and showcase early data from their new technology. This event is pivotal for labs planning to adopt Ultima's advanced sequencing platforms. The workshop will highlight the operational successes achieved with paired-end sequencing and the Solaris 2.0 Max, fostering collaboration among researchers and clinicians.

Join Ultima Genomics at their booth (#1009) during the ASHG Exhibit, from October 21 to October 23, to learn more about how these innovations are set to revolutionize genomic research and clinical applications.

The Future of Genomics

Ultima Genomics is not just about keeping pace with the latest technology. Their mission is to drive down the cost of genomic information and broaden access to advanced sequencing tools that unlock new biological and health advancements. As the field stands on the brink of a new biological revolution, Ultima is committed to breaking barriers associated with conventional sequencing technologies.

In summary, Ultima Genomics is reshaping the future of genomics with innovations that promise cost-effective and high-quality sequencing options. As they roll out paired-end sequencing and Solaris 2.0 Max, the implications for healthcare, research, and biotechnology are immense, ultimately aiming to transform human health and biology's understanding.